-
公开(公告)号：US20170232030A1
公开(公告)日：2017-08-17
申请号：US15503542
申请日：2015-08-12
Applicant: Epizyme, Inc. , Celgene Corporation
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock , Vivek Chopra
IPC: A61K31/7064 , A61K31/7068 , A61K31/519 , A61K45/06 , A61K31/706
CPC classification number: A61K31/7064 , A61K31/135 , A61K31/136 , A61K31/4045 , A61K31/4745 , A61K31/519 , A61K31/5377 , A61K31/704 , A61K31/706 , A61K31/7068 , A61K31/7076 , A61K45/06 , A61P35/00 , A61K2300/00
Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20180028552A1
公开(公告)日：2018-02-01
申请号：US15547427
申请日：2016-02-01
Applicant: Epizyme, Inc. , Celgene Corporation
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock , Vivek Chopra
IPC: A61K31/7076 , A61K31/706
CPC classification number: A61K31/7076 , A61K31/706 , A61K31/7068 , A61K2300/00
Abstract: The present disclosure relates to a combination of an inhibitor of human histone methyltransferase DOT1L, such as EPZ-5676 or salts thereof, and one or more DNMT inhibitors, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20190083521A1
公开(公告)日：2019-03-21
申请号：US15512527
申请日：2015-08-12
Applicant: Epizyme, Inc.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , A61K31/7068 , A61K31/704 , A61K31/706 , A61K31/519 , A61K45/06 , A61P35/02 , A61K31/136 , A61K31/135 , A61K31/635 , A61K31/5377
Abstract: The disclosure relates to combinations comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
-
公开(公告)号：US20160045531A1
公开(公告)日：2016-02-18
申请号：US14776669
申请日：2014-03-14
Applicant: EPIZYME, INC.
Inventor： Christine Klaus , Maria Alejandra Raimondi , Scott Richard Daigle , Roy MacFarlane Pollock
IPC: A61K31/7076 , C07H19/044 , A61K31/7064 , A61K31/551 , A61K31/704 , A61K31/706 , A61K31/136 , A61K31/4745 , C07H19/16 , A61K31/7068
CPC classification number: A61K31/7076 , A61K31/136 , A61K31/4745 , A61K31/551 , A61K31/704 , A61K31/706 , A61K31/7064 , A61K31/7068 , C07H19/044 , C07H19/16 , A61K2300/00
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Abstract translation: 本发明涉及包含人组蛋白甲基转移酶DOT1L的抑制剂和一种或多种治疗剂，特别是抗癌剂的组合物，以及用于给予需要其治疗癌症的受试者的组合疗法的方法。
-
Patent Agency Ranking
公开(公告)号：US20150216890A1
公开(公告)日：2015-08-06
申请号：US14426331
申请日：2013-09-06
Applicant: Epizyme, Inc.
Inventor： Edward J. Olhava , Richard Chesworth , Kevin W. Kuntz , Victoria M. Richon , Roy M. Pollock , Scott Richard Daigle
IPC: A61K31/7076
CPC classification number: A61K31/7076 , A61K31/52
Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
Abstract translation: 本发明涉及通过向有需要的受试者施用DOT1L抑制剂化合物和药物组合物来治疗其中DOT1L介导的蛋白质甲基化部分如癌症的病症的方法。
-
公开(公告)号：US11633420B2
公开(公告)日：2023-04-25
申请号：US17140331
申请日：2021-01-04
Applicant: Epizyme, Inc.
Inventor： Edward J. Olhava , Richard Chesworth , Kevin W. Kuntz , Victoria M. Richon , Roy M. Pollock , Scott Richard Daigle
IPC: A61K31/7076 , A61K31/52
Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号：US10881680B2
公开(公告)日：2021-01-05
申请号：US16214783
申请日：2018-12-10
Applicant: Epizyme, Inc.
Inventor： Edward J. Olhava , Richard Chesworth , Kevin W. Kuntz , Victoria M. Richon , Roy M. Pollock , Scott Richard Daigle
IPC: A61K31/7076 , A61K31/52
Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号：US20170165288A1
公开(公告)日：2017-06-15
申请号：US15387240
申请日：2016-12-21
Applicant: Epizyme, Inc.
Inventor： Edward J. Olhava , Richard Chesworth , Kevin W. Kuntz , Victoria M. Richon , Roy M. Pollock , Scott Richard Daigle
IPC: A61K31/7076
CPC classification number: A61K31/7076 , A61K31/52
Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
-
公开(公告)号：US09597348B2
公开(公告)日：2017-03-21
申请号：US14426331
申请日：2013-09-06
Applicant: Epizyme, Inc.
Inventor： Edward J. Olhava , Richard Chesworth , Kevin W. Kuntz , Victoria M. Richon , Roy M. Pollock , Scott Richard Daigle
IPC: A61K31/7076 , A61K31/52
CPC classification number: A61K31/7076 , A61K31/52
Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.018 seconds)
